TY - JOUR
T1 - Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC
T2 - A Case Series
AU - Le, Xiuning
AU - Eisert, Anna
AU - Hsia, Te-Chun
AU - Raut, Nirmal Vivek
AU - Ahmad, Azura
AU - Chan, Oscar Siu Hong
AU - De Bondt, Charlotte
AU - Farrugia, David
AU - Froesch, Patrizia
AU - González-Cao, Maria
AU - Hendriks, Lizza
AU - Hochmair, Maximillian J
AU - Mazieres, Julien
AU - O'Sullivan, Hazel
AU - Popat, Sanjay
AU - Samol, Jens
AU - van der Wekken, Anthonie J
AU - Yang, Tsung-Ying
AU - Tho, Lye Mun
AU - Himpe, Ulrike
AU - Lam, Wei-Sen
AU - Lee, Kirsty Wai Chung
AU - Petrini, Iacopo
AU - Berghoff, Karin
AU - Karachaliou, Niki
AU - Joshi, Kirti
AU - Vlassak, Soetkin
AU - Chang, Gee-Chen
PY - 2025/2/21
Y1 - 2025/2/21
N2 - • No targeted treatments are currently approved for patients with EGFR-mutant non–small-cell lung cancer (NSCLC) and MET-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). • This case series describes real-world outcomes with tepotinib, a selective MET-TKI, in combination with EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC and resistance to EGFR-TKIs. • Among the 25 patients included, tepotinib was given in combination with a range of EGFR-TKIs (osimertinib, n = 18; gefitinib, n = 5; dacomitinib, n = 1; afatinib, n = 1) as second (n = 8), third (n = 9), or fourth-or-later (n = 8) line therapy. • Tepotinib plus EGFR-TKIs demonstrated clinical benefit per physician's assessment in 23/25 patients, with a partial response in 15/25 patients. • Tepotinib plus EGFR-TKIs showed favorable tolerability that was consistent with previous observations, with edema reported as the most common tepotinib-related adverse event (14/25 patients). • This case series, including patients with several prior treatment lines, suggest tepotinib plus an EGFR-TKI as a potential chemotherapy-sparing, oral targeted treatment option for patients with EGFR‑mutated, MET-altered NSCLC after progression on EGFR‑TKIs.
AB - • No targeted treatments are currently approved for patients with EGFR-mutant non–small-cell lung cancer (NSCLC) and MET-mediated resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). • This case series describes real-world outcomes with tepotinib, a selective MET-TKI, in combination with EGFR-TKIs in patients with EGFR-mutant, MET-altered NSCLC and resistance to EGFR-TKIs. • Among the 25 patients included, tepotinib was given in combination with a range of EGFR-TKIs (osimertinib, n = 18; gefitinib, n = 5; dacomitinib, n = 1; afatinib, n = 1) as second (n = 8), third (n = 9), or fourth-or-later (n = 8) line therapy. • Tepotinib plus EGFR-TKIs demonstrated clinical benefit per physician's assessment in 23/25 patients, with a partial response in 15/25 patients. • Tepotinib plus EGFR-TKIs showed favorable tolerability that was consistent with previous observations, with edema reported as the most common tepotinib-related adverse event (14/25 patients). • This case series, including patients with several prior treatment lines, suggest tepotinib plus an EGFR-TKI as a potential chemotherapy-sparing, oral targeted treatment option for patients with EGFR‑mutated, MET-altered NSCLC after progression on EGFR‑TKIs.
KW - EGFR-TKI resistance
KW - MET amplification
KW - MET exon 14 skipping
KW - Non-small-cell lung cancer
U2 - 10.1016/j.cllc.2025.02.013
DO - 10.1016/j.cllc.2025.02.013
M3 - Article
SN - 1525-7304
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
ER -